Neisserial Surface Protein A Vaccine Antigens With Decreased Binding To Human Complement Factor H

Value Proposition

There is currently a lack of licensed vaccine for protection against gonorrhea and other gonococcal diseases and a limited protection afforded by meningococcal group B vaccines, especially in infants. There are ~ 100 M cases of gonorrhea each year globally, making it the second most common bacterial sexually transmitted infection worldwide.

Technology Description

UCSF investigators have developed mutant versions of several bacterial antigens and have shown that that these increased vaccine immunogenicity and protection compared to their native counterparts in relevant animal models.